Tissue Repair (ASX:TRP) has secured a TGA approval for TR Pro+™, the Company’s first advanced wound healing gel product containing the proprietary active ingredient, Glucoprime® (0.1%), derived from yeast.
TR Pro+™ was launched in June 2023 and “represents a new standard in the aftercare of medical and aesthetic procedures.” The TGA listing will enable Tissue Repair to promote its considerable scientific and clinical data more broadly.
Tissue Repair will shortly provide a broader more detailed update presentation from its co-founder and Executive Director Tony Charara in relation to this “significant development” and the Company’s broader strategies in the immediate commercialisation of its proprietary technology as well as the imminent commencement of Phase 3 clinical trials for its advanced wound drug candidate TR987®.